#153630

RalGDS Floxed Mouse

Cat. #153630

RalGDS Floxed Mouse

Cat. #: 153630

Sub-type: Mouse

Availability: 6-8 weeks

Disease: Melanoma

Model: Conditional KO

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Chris Marshall

Institute: The Institute of Cancer Research

Tool Details
Handling
Target Details
Related Tools
References

Tool Details

*FOR RESEARCH USE ONLY

  • Tool name: RalGDS Floxed Mouse
  • Alternate name: Friend Virus B, Ral Guanine Nucleotide Dissociation Stimulator, Ral Guanine Nucleotide Exchange Factor, RalGEF, RGF, KIAA138, RalGDS, RGDS
  • Research fields: Cancer;Cell signaling and signal transduction;Genetics
  • Tool sub type: Mouse
  • Disease: Melanoma
  • Model: Conditional KO
  • Conditional: Yes
  • Description: The knock-out mouse was developed by Chris Marshall at the ICR and used to demonstrate a significant role for RalGDS in Ras-dependent carcinogenesis in vivo. Lack of RalGDS resulted in reduced tumour incidence, size and progression to malignancy in multistage skin carcinogenesis, and reduced transformation by Ras in tissue culture. Experiments performed in cells isolated from skin tumours suggested that RalGDS mediates cell survival through the activation of the JNK/SAPK pathway. Mouse deficient in RalGDS (a member of the RalGEF family, which control the activity of the small GTPases RalA and RalB, and also have Ras binding domains).
  • Genetic background: Mouse RalGDS genomic clones were obtained by screening a 129/SvJ BAC library. A targeting vector was designed using a DNA fragment extending from intron 7 to the 3'UTR, cloned into the pKO scrambler 901 vector. A neomycin cassette flanked by two loxP sites was cloned upstream of exon 16 and a 3rd loxP site was located in exon 8. The exons flanked by loxP sites comprise part of the catalytic domain of RalGDS and residues involved in the binding of the exchange factor to Ras. The construct was electroporated into RW4 ES cells and clones positive for recombination were then transiently transfected with pcrePac vector to eliminate the neomycin cassette. Cells carrying the RalGDS allele lacking exons 9-15 were injected into MF-1 blastocysts and germline-transmitting chimeric mice were obtained. As a result of Cre-mediate recombination, a RasGDS floxed allele in which loxP sites flank the exon 9-15 region was obtained.
  • Zygosity: Homozygous
  • Production details: Mouse RalGDS genomic clones were obtained by screening a 129/SvJ BAC library. A targeting vector was designed using a DNA fragment extending from intron 7 to the 3'UTR, cloned into the pKO scrambler 901 vector. A neomycin cassette flanked by two loxP sites was cloned upstream of exon 16 and a 3rd loxP site was located in exon 8. The exons flanked by loxP sites comprise part of the catalytic domain of RalGDS and residues involved in the binding of the exchange factor to Ras. The construct was electroporated into RW4 ES cells and clones positive for recombination were then transiently transfected with pcrePac vector to eliminate the neomycin cassette. Cells carrying the RalGDS allele lacking exons 9-15 were injected into MF-1 blastocysts and germline-transmitting chimeric mice were obtained. As a result of Cre-mediate recombination, a RasGDS floxed allele in which loxP sites flank the exon 9-15 region was obtained.

Handling

  • Shipping conditions: Embryo/Spermatoza- Dry Ice

Target Details

  • Target: RalGDS

Related Tools

  • Related tools: RalGDS KO Mouse

References

  • Gonzlez-Garca et al. 2005. Cancer Cell. 7(3):219-26. PMID: 15766660.
  • RalGDS is required for tumor formation in a model of skin carcinogenesis.